6-氯-3-吡啶基乙酸酯 | 188057-24-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-氯-3-吡啶基乙酸酯
• 中文别名: 6-氯吡啶-3-基乙酸酯；5-乙酰基氧基-2-氯吡啶
• 英文名称: 5-Acetoxy-2-chloropyridine
• 英文别名: 2-chloro-5-acetoxypyridine；acetic acid 6-chloro-pyridin-3-yl ester；6-Chloropyridin-3-yl acetate；(6-chloropyridin-3-yl) acetate
• CAS: 188057-24-1
• 化学式: C₇H₆ClNO₂
• mdl: MFCD05863252
• 分子量: 171.583
• InChiKey: NWKLWOGUAXAQGW-UHFFFAOYSA-N

物化性质

• 沸点：
  260.4±25.0 °C(Predicted)
• 密度：
  1.297±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  6-氯-3-吡啶基乙酸酯 在 palladium diacetate 四丁基氯化铵 、 碘 、 sodium formate 、 sodium carbonate 、 potassium carbonate 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 Methyl 2-(5-chloro-2-propylfuro[3,2-b]pyridin-3-yl)acetate
  参考文献：
  名称：

  A general method for the preparation of 2,3,5-trisubstituted-furo[3,2-b]pyridines

  摘要：

  The preparation of 2,3,5-trisubstituted-furo[3,2-b]pyridines via a Pd(0)-catalyzed intramolecular cyclization of methyl 4-(6-chloro-2-iodopyridin-3-yloxy)-substituted-butenoates 9a-f is described. This approach was both efficient and general, and provided the highly functionalized heterocyclic ring system in high yield. Among the several examples provided is the preparation of 3-[2-(N,N-dimethylamino)ethyl]-5-(4-fluorobenzoyl)amino-2-methylfuro[3,2-b]pyridine 4, a selective 5-HTIF receptor agonist. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(02)02655-2
• 作为产物：
  描述：

  2-氯-5-氨基吡啶 生成 6-氯-3-吡啶基乙酸酯
  参考文献：
  名称：

  Tetrahedron Asymmetry. 1998, 9, 2791-2794

  摘要：

  DOI：

文献信息

• Benzimidazoles that are useful in treating sexual dysfunction
  申请人：——

  公开号：US20030008878A1

  公开（公告）日：2003-01-09

  The present invention relates to the use of compounds of formula (I) 1 for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.

  本发明涉及使用式（I）的化合物治疗性功能障碍，以及含有式（I）的化合物的组合物用于治疗性功能障碍。
• Heterocyclic compounds useful as pharmaceutical agents
  申请人：Zeneca Limited

  公开号：US06313127B1

  公开（公告）日：2001-11-06

  Compounds of formula (I) in which all variables are defined in the description and their salts inhibit the enzyme oxido squalene cyclase and are useful in treating hypercholesterolemia and also as anti-fungal agents. Processes for their preparation are also described together with their use in medicine.

  式(I)的化合物 其中所有变量在描述中定义，并且它们的盐抑制酶氧化甾二烯环化酶，在治疗高胆固醇血症和作为抗真菌剂方面具有用处。还描述了它们的制备过程以及它们在医学上的用途。
• Furopyridine, thienopyridine pyrrolopyridine useful in controlling
  申请人：Abbott Laboratories

  公开号：US06001849A1

  公开（公告）日：1999-12-14

  Novel heterocyclic ether compounds having the formula: ##STR1## wherein A, m, R, X, Y.sup.1, Y.sup.2 and Y.sup.3 are specifically defined, which are useful in selectively controlling chemical synaptic transmission; therapeutically-effective pharmaceutical compositions thereof; and use of said compositions to selectively control synaptic transmission in mammals.

  具有以下结构的新型杂环醚化合物：##STR1## 其中A、m、R、X、Y.sup.1、Y.sup.2和Y.sup.3具体定义，可用于选择性控制化学突触传递；其治疗有效的药物组成物；以及利用该组成物在哺乳动物中选择性控制突触传递。
• [EN] TRIAZOLO-PYRIDINES AS ANTI-INFLAMMATORY COMPOUNDS<br/>[FR] TRIAZOLO-PYRIDINES UTILISEES COMME COMPOSES ANTI-INFLAMMATOIRES
  申请人：PFIZER PROD INC

  公开号：WO2004072072A1

  公开（公告）日：2004-08-26

  The present invention relates to novel triazolo-pyridines of the formula (I) wherein X is >CH2, >NH, sulfur, >S=O, >S02 or oxygen; wherein said >CH2 and >NH may optionally be substituted with a suitable substituent; R1 is selected from the group consisting of hydrogen, (C1-C6)alkyl and other suitable substituents; R2 is selected from the group consisting of hydrogen, (Cl-C6)alkyl and other suitable 10 substituents; s is an integer from 0-4; R3 is R4, R5-(NR6)-, R5-S-, R5-(S=O)-, R5-(S02)-, R5-S02-NR6-, R5-(NR6)-S02-, R5-O-,R5-(C=O)-, R5-(NR6)-(C=O)-, R5-(C=O)-NR6-, R5-O-(C=O)-, R5-(C=O)-O-, R5-CR7=CR8- or R5-C=-C-; such that the molecular weight of R3 is less than 500 AMU, preferably less than 250 15 AMU; R4, R5 and R6 are each selected from the group consisting of hydrogen, (C1-C6)alkyl and other suitable substituents; or a pharmaceutically acceptable salt thereof; to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明涉及具有以下式(I)的新型三唑吡啶，其中X为>CH2，>NH，硫，>S=O，>SO2或氧；其中所述的> 和>NH可以选择性地被适当的取代基取代；R1选自氢，(C1-C6)烷基和其他适当的取代基组成的群；R2选自氢，(Cl-C6)烷基和其他适当的取代基组成的群；s为0-4的整数；R3为R4，R5-(NR6)-，R5-S-，R5-(S=O)-，R5-(SO2)-，R5-SO2-NR6-，R5-(NR6)-SO2-，R5-O-，R5-(C=O)-，R5-(NR6)-(C=O)-，R5-(C=O)-NR6-，R5-O-(C=O)-，R5-(C=O)-O-，R5-CR7=CR8-或R5-C=-C-；使得R3的分子量小于500 AMU，最好小于250 AMU；R4，R5和R6分别选自氢，(C1-C6)烷基和其他适当的取代基组成的群；或其药学上可接受的盐；用于它们的制备的中间体，含有它们的药物组合物以及它们的药用。本发明的化合物是MAP激酶的有效抑制剂。它们在治疗炎症、骨关节炎、类风湿关节炎、癌症、中风或心脏病发作中的再灌注或缺血、自身免疫疾病和其他疾病中具有用途。
• 5-HT1F agonists
  申请人：Eli Lilly and Company

  公开号：US06696439B1

  公开（公告）日：2004-02-24

  The present invention relates to substituted furo[3,2-b]pyridine compounds of formula I: or a pharmaceutical acid addition salt thereof; where; R is E—D is C═CH or CH—CH2; R1 is hydrogen or C1-C4 alkyl; R2 is hydrogen, halo, hydroxy, —NR3R4, —SR3, —C(O)R3, —C(O)MR3R4, —NR3SO2R5, —NHC(Q)NR3R4, —NHC(O)OR3, or —NR3C(O)R5; R3, R4, and R5 are independently hydrogen, C1-C4 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or —(CH2)naryl; or R3 and R4 combine, together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, piperazine, 4-substituted piperazine, morpholine, or thiomorpholine ring; n is 0, 1, 2, 3, 4, 5, or 6; and Q is O or S. The present invention further relates to pharmaceutical. formulations containing compounds formula I and to the use of compounds of formula I for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and treating and/or preventing migraine in a mammal.

  本发明涉及以下式I的取代呋喃[3,2-b]吡啶化合物或其药用酸盐；其中；R为E—D为C═CH或CH—CH2；R1为氢或C1-C4烷基；R2为氢、卤素、羟基、—NR3R4、—SR3、—C(O)R3、—C(O)MR3R4、—NR3SO2R5、—NHC(Q)NR3R4、—NHC(O)OR3或—NR3C(O)R5；R3、R4和R5独立地为氢、C1-C4烷基、C2-C6烯基、C2-C6炔基或—( )n芳基；或R3和R4结合，与它们连接的氮一起形成吡咯烷、哌咯烷、哌嗪、4-取代哌嗪、吗啉或硫代吗啉环；n为0、1、2、3、4、5或6；Q为O或S。本发明还涉及含有式I化合物的制剂以及利用式I化合物激活5-HT1F受体、抑制神经蛋白外渗，并在哺乳动物中治疗和/或预防偏头痛。